Listed

XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2022

Filed with the SEC on Mar 22, 2023 and accepted by EDGAR at Mar 22, 2023, 12:00 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2022-01-01 to 2022-12-31−$880.0kifrs-full:ProfitLossFromOperatingActivities
Net income12 months2022-01-01 to 2022-12-31−$1.3mifrs-full:ProfitLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−$0.00ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2022-01-01 to 2022-12-31−$0.00ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2022-01-01 to 2022-12-31−$901.0kifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2022-12-31$2.1mifrs-full:CashAndCashEquivalents
Current assetsAt period end2022-12-31$3.8mifrs-full:CurrentAssets
Total assetsAt period end2022-12-31$4.2mifrs-full:Assets
Shareholders' equityAt period end2022-12-31$4.0mifrs-full:Equity
Shares outstandingAt period end2022-12-31544,906,149 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001213900-23-021869. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.